Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven M Francque

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Hepatology (Baltimore, Md.)|May 7, 2025
Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunctionLaurens A van Kleef, Jesse Pustjens, Jörn M Schattenberg, et al.
Journal of the American College of Cardiology|February 4, 2026
MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial DesignFaiez Zannad, Muhammad Shahzeb Khan, Nisha Bansal, et al.
JHEP Reports : Innovation in Hepatology|June 5, 2023
Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetesJonathan Mertens, Jonas Weyler, Eveline Dirinck, et al.
Gut|December 31, 2025
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunitiesXiao-Dong Zhou, Qiong-Yue Fan, Christopher D Byrne, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitisVlad Ratziu, Pierre Bedossa, Sven M Francque, et al.
British Journal of Pharmacology|June 19, 2018
Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndromeHannah Ceuleers, Nikita Hanning, Jelena Heirbaut, et al.
JHEP Reports : Innovation in Hepatology|October 25, 2021
Non-alcoholic fatty liver disease: A patient guidelineSven M Francque, Giulio Marchesini, Achim Kautz, et al.
Gastroenterology|March 21, 2024
Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic DysfunctionLaurens A van Kleef, Sven M Francque, Jhon E Prieto-Ortiz, et al.
Cell Death and Differentiation|August 15, 2023
Ferroptosis and pyroptosis signatures in critical COVID-19 patientsCédric Peleman, Samya Van Coillie, Symen Ligthart, et al.
Gastroenterology|June 15, 2026
Validated early detection metrics reduce the population requiring liver fibrosis screeningLaurens A van Kleef, Jesse Pustjens, Carolin V Schneider, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Hepatology (Baltimore, Md.)|May 7, 2025
Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunctionLaurens A van Kleef, Jesse Pustjens, Jörn M Schattenberg, et al.
Journal of the American College of Cardiology|February 4, 2026
MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial DesignFaiez Zannad, Muhammad Shahzeb Khan, Nisha Bansal, et al.
JHEP Reports : Innovation in Hepatology|June 5, 2023
Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetesJonathan Mertens, Jonas Weyler, Eveline Dirinck, et al.
Gut|December 31, 2025
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunitiesXiao-Dong Zhou, Qiong-Yue Fan, Christopher D Byrne, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitisVlad Ratziu, Pierre Bedossa, Sven M Francque, et al.
British Journal of Pharmacology|June 19, 2018
Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndromeHannah Ceuleers, Nikita Hanning, Jelena Heirbaut, et al.
JHEP Reports : Innovation in Hepatology|October 25, 2021
Non-alcoholic fatty liver disease: A patient guidelineSven M Francque, Giulio Marchesini, Achim Kautz, et al.
Gastroenterology|March 21, 2024
Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic DysfunctionLaurens A van Kleef, Sven M Francque, Jhon E Prieto-Ortiz, et al.
Cell Death and Differentiation|August 15, 2023
Ferroptosis and pyroptosis signatures in critical COVID-19 patientsCédric Peleman, Samya Van Coillie, Symen Ligthart, et al.
Gastroenterology|June 15, 2026
Validated early detection metrics reduce the population requiring liver fibrosis screeningLaurens A van Kleef, Jesse Pustjens, Carolin V Schneider, et al.
Pageof 6